ISPOR Europe 2025
9-12 November 2025 | Glasgow, Scotland, UK

Burden of Disease and Healthcare Resource Use in Patients with Hereditary Transthyretin Amyloidosis in Spain: Findings from the OverTTuRe Global Study

LUCÍA GALÁN-DÁVILA[1], PABLO GARCÍA-PAVÍA[2], MARGARITA CAPEL-SÁNCHEZ[3], MARTA CASTRO-GASCH[3], SERGIO CEDILLO[3], ALICIA EISMAN-MARAVER[4], KRISTER JÄRBRINK[5], JOAQUÍN SÁNCHEZ-COVISA[4]

1. Neurology Service, Hospital Universitario Clínico San Carlos, Madrid, Spain; 2. Cardiology Service, Hospital Universitario Puerta de Hierro, Majadahonda, Spain; 3. Corporate Affairs and Market Access Department, BioPharmaceuticals, AstraZeneca, Madrid, Spain; 4. Medical and Regulatory Affairs Department, BioPharmaceuticals Medical, AstraZeneca, Madrid, Spain; 5. Cardiovascular, Renal and Metabolism Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden

Poster #: **HSD16**

1 INTRODUCTION

- **Hereditary transthyretin (ATTRv) amyloidosis is a rare, progressive, life-threatening disease** caused by variants resulting in amyloid accumulation in organs and tissues.
- It mainly presents with peripheral and autonomic neuropathy, but can also affect the heart, kidneys, and eyes.

2 OBJECTIVE

- OverTTuRe's objective is to **provide a comprehensive review of the disease's natural history.**
- This analysis presents **data from Spain,** focusing on **healthcare resource use and mortality.**

3 METHOD

- **Retrospective observational study of medical records from 11 Spanish hospitals.** The Coutinho staging, used to assess polyneuropathy severity - ranging from 0 (presymptomatic) to 3 (inability to walk)- was collected

Figure 1. *Study flow diagram*



4 RESULTS

60.8% *Male* | **39.2%** *Female*

n=212 (160 with Coutinho staging available)

Mean age at Dx: 60.9 years (SD=15.2)

Median time from first manifestation to diagnosis: 7.9 months (IQR=0.6-44.6)

Average follow-up: 57.9 months (SD=38.4)

Figure 2. *Coutinho staging (%) (n=160)*



Healthcare resource use

- During follow-up, 40.1% were hospitalized at least once, 58.9% visited the ER and 95.2% visited a specialist.
- Mean hospital length of stay was 10 days (SD: 18.8)

Figure 3. *Healthcare resource use (%)*



Mortality (overall follow-up) → **14.4%** (13.3% in Coutinho 1-2).

Figure 4. *Healthcare resource use per patient per year (PPPY) (mean).*
A: *hospitalizations and ER visits;* ***B:*** *specialist visits*



ER: emergency room; SD: standard deviation; Dx: diagnosis; PPPY: per patient per year; IQR: interquartile range

5 CONCLUSIONS

ATTRv amyloidosis imposes a substantial burden on patients and the healthcare system, as evidenced by **high rates of hospitalizations, ER visits, specialist consultations, and mortality** even in early stages.

These findings underscore an **urgent need for improved clinical management and initiation of disease-modifying therapies** to mitigate the impact of **this progressive condition.**

Disclosures: NM-M, AA, TL, CC and JS-C are AstraZeneca employees. No other conflicts to declare.

Presented at the ISPOR Europe 2025 Congress, Glasgow, Scotland, UK, October 2025

OVERTTURE an ANTHOLOGY study

Sponsored by AstraZeneca